BIO tripled in three days, is DeSci an old tree blooming anew?
- Core Thesis: Bio Protocol, by upgrading its narrative from DeSci to AI Agent-driven DeSci (Agentic DeSci) and launching the BioXP system and BioAgent Launchpad, has built a positive flywheel of "staking - new token issuance (launchpad) - governance", propelling the BIO token to double in value within three days. However, the team moving tokens to exchanges and the sector's reliance on narrative speculation introduce uncertainty for the future.
- Key Elements:
- The price of the BIO token briefly surpassed $0.066 on May 3rd, doubling in three days, before pulling back to around $0.06. Its market cap is currently reported at $127 million, significantly lower than its high of $1.1 billion at the beginning of the year.
- Narrative upgrade was key: shifting from Decentralized Science (DeSci) to AI Agent-driven DeSci, launching the BioXP system used for prioritized access to new token offerings and accumulating governance voting power (veBIO).
- The ecosystem's token launch project, PeptAI, went live on May 1st, reaching 5.9x oversubscription within 30 minutes. As of May 4th, it was oversubscribed by 12.7x ($633,000), with over 700 participants, forming a positive cycle of staking BIO -> earning BioXP -> participating in launches -> governance.
- The Bio Protocol ecosystem has raised over $50 million in total funding, with a community of approximately 90,000 members. It previously completed a $6.9 million seed round led by Arthur Hayes' Maelstrom Fund.
- The team's multi-sig address transferred 120 million BIO (worth approximately $5.031 million) to an exchange on May 3rd, sparking concerns of a "pump and dump" scheme, although the price impact was minimal.
- The latest project, PEPTAI, has entered the wet lab phase. It operates on a model of "AI Agent autonomous decision-making + on-chain information transparency," pushing DeSci towards a genuine business stage of "reproducible drug discovery pipeline."
- Short-term price action remains highly dependent on narrative speculation, but the team is targeting the multi-trillion dollar healthcare market, demonstrating significant ambition.
Original｜Odaily Planet Daily (@OdailyChina)
Author｜Wenser (@wenser 2010 )
In the gradually warming crypto market, the former "DeSci track star"—BIO—has also delivered an impressive report card: On May 3, its price briefly broke through $0.066, doubling in just 3 days. Nearly a year and a half after the DeSci (Decentralized Science) hype at the end of 2024, Bio Protocol, once bearing the halo of a "Binance Launchpool project," is now riding the AI trend with the slogan "Agent Pays for Science." Whether this is an old tree blooming anew or a pump-and-dump scheme, we may soon find out.
Bio Protocol's Old and New Narratives: From DeSci to Agentic DeSci
Analyzing the drivers behind BIO's price increase, in my view, the most important factor is its alignment with the new narrative of the AI era—shifting from decentralized scientific research to AI Agent and agent-driven decentralized scientific research.
This is not only a further refinement of its market positioning but also a crucial step to inject new vitality into the Bio Protocol ecosystem. Specifically, Bio Protocol's key actions are as follows:
- BioXP System: Built on the Bio Protocol V2 staking system, the BioXP system allows for priority participation in Ignition Sales, increased allocation quotas, and accumulation of veBIO (governance voting power). This is the foundational framework for long-term ecosystem building.
- Funding Support: In September last year, Bio Protocol completed a $6.9 million seed round led by Arthur Hayes' Maelstrom Fund, with participation from Mechanism Capital, Animoca Brands, Presto Labs, etc., to advance the AI-driven Launchpad and BioAgents. It also previously received investment from Yzi Labs (formerly Binance Labs). Sufficient funding is a necessary guarantee for continued development through bull and bear cycles.
- BioAgent Launchpad: Built on the BioAgents platform, this Launchpad focuses on the concept of "allowing anyone to deploy DeSci AI agents." The latest offering,PeptAI, launched on May 1, was oversubscribed by 5.9 times in under 30 minutes. As of May 4, it was oversubscribed by 12.7 times ($633,000, with a token launch FDV of $1 million, implying a token price of $0.10). Over 700 participants have joined; the sale period is 14 days, ending at 9 PM on May 14. Regarding token distribution: 20% of the total PEPTAI supply will be airdropped to BIO stakers (veBIO holders, with a 6-month linear unlock); 5% is offered publicly through the Ignition Sale; those without BioXP can participate by minting or staking BIO directly. Thus, via the Launchpad mechanism, Bio Protocol has created a positive flywheel: "Stake BIO tokens → Earn BioXP points → Participate in project sales → Engage in community governance."
According to official data, the Bio ecosystem's total fundraising has exceeded $50 million, with a community of approximately 90,000 members.
Driven by this new flywheel effect, the BIO token continued its previous upward momentum within just 3 days, surging from around $0.03 to $0.066, before currently retreating to around $0.06.
Of course, while narrative updates and project iteration are one side of the coin, the Bio Protocol team's market-making or potential distribution efforts are another focal point for the market.
Pump-and-Dump or Active Market Making? A Look at the Bio Protocol Team's Ambition
On the morning of May 3, according to monitoring by crypto analyst Ai Yi @ai_9684xtpa, BIO rose 118% over the past week. That day, the Bio Protocol team's multi-sig address transferred 120 million BIO to three addresses, of which approximately 80 million were sent to OKX and Binance, valued at about $5.031 million.
On the other hand, Binance previously announced it would add the BIO/U trading pair on cross-margin at 16:00 (UTC+8) on April 28, 2026, adding fuel to BIO's upward momentum from a leverage perspective.
Currently, BIO's market cap stands at approximately $127 million, still far from its all-time high of around $1.1 billion in early 2025. The team's operation did not cause significant price volatility. Coupled with the broader crypto market recovering above $80,000, BIO's price could continue to rise.
Furthermore, and more importantly, the latest project on the Bio Protocol ecosystem, PEPTAI, has entered the wet lab research phase. Operating on a model of "Autonomous AI Agent decision-making + on-chain information transparency," it has pushed the DeSci track, which was previously more focused on the proof-of-concept stage, towards a real-world "reproducible drug discovery assembly line" phase.
From this perspective, the Bio Protocol team's ambition has never been small. They are, after all, targeting a healthcare market with a trillion-dollar market cap.
Of course, considering the niche nature and regulatory hurdles of the DeSci track, the price trajectory of the BIO token for the rest of the year will likely remain highly dependent on narrative-driven speculation in the short term.
Recommended Reading:
The Light of DeSci? A Deep Dive into Binance Launchpool's Latest Project, BIO
